New sedative in intensive care, Dexmedetomidine hydrochloride (Precedex), its pharmacological characteristics and clinical study result.

DOI Web Site PubMed 10 Citations 28 References
  • TAIJI Kazuko
    Development & Regulatory, Therapeutic Group 1, Abbott Japan Co., Ltd

Bibliographic Information

Other Title
  • 集中治療における新しい鎮静薬　塩酸デクスメデトミジン（プレセデックス）の薬理学的特徴と臨床試験成績
  • 新薬紹介総説 集中治療における新しい鎮静薬塩酸デクスメデトミジン(プレセデックス)の薬理学的特徴と臨床試験成績
  • シンヤク ショウカイ ソウセツ シュウチュウ チリョウ ニ オケル アタラシイ チンセイヤク エンサン デクスメデトミジン プレセデックス ノ ヤクリガクテキ トクチョウ ト リンショウ シケン セイセキ
  • Dexmedetomidine hydrochloride (Precedex), a new sedative in intensive care, its pharmacological characteristics and clinical study result

Search this article

Description

Dexmedetomidine hydrochloride (Precedex) is a potent and highly selective central α2-adrenoreceptor agonist. In a test of affinity to receptors in rat brain cortex, this drug showed a high affinity and selectivity to the α2-adrenoreceptor. This drug induced a dose-dependent decrease in activity, loss of righting reflex, an increase in sedation score, and a dose-dependent prolongation of the latent time of escape from pain in various animal models. The site of action for the sedative action of this drug is considered to be the locus coeruleus. With administration of this drug into the locus coeruleus, loss of righting reflex was observed in almost all animals. Test results using mice with variant α2A-receptor suggested that the sedative action of this drug is expressed through the α2A-receptor subtype. This drug is promptly eliminated from blood. In the phase II/III multi-center placebo-controlled double blind bridging study conducted in Japan, efficacy and safety were examined in patients brought to the ICU. As regards sedative action, the ratio of patients who did not require additional propofol medication (>50 mg) while intubated was taken as the effective rate. The drug group showed a significantly high effective rate (90.9%; placebo group, 44.6%). Similarly, with analgesic action, the ratio of patients who did not require additional morphine medication during intubation was taken as the effective rate. The effective rate for the drug group was significantly high (87.3%; placebo group, 75.0%). The main adverse events observed in the drug group were hypertension and hypotension.<br>

Journal

Citations (10)*help

See more

References(28)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top